In a Morning Consult commentary, IVI Executive Director, Jennifer Bright, discusses why transparency is a prerequisite to value-based reimbursement and how IVI's Open-Source Value Platform (OSVP) is an open laboratory for creating sophisticated systems to assess value in healthcare. Read the full article here.
In Tomas Philipson's latest Forbes.com op-ed, he examines the challenges of value assessment in the U.S. healthcare system and describes a decentralized approach to assessing value that better suits the U.S. context. Using IVI as an example, Philipson outlines several key criteria that a decentralized value assessment approach should meet in order to effectively link [...]
In a recent post on the IVI-sponsored Health Affairs blog series, David Tawes and Marta Wosinka examine consequences of the disconnection between market prices and reimbursement, specifically in that Medicare still uses 2003 average wholesale prices (AWPs) for some drugs. Tawes and Wosinka point out that, in the case of drugs where the actual costs [...]
